Summary
An unequitable vaccine allocation and continuously emerging SARS-CoV-2 variants pose challenges to contain the pandemic, which underscores the need for licensing more vaccine candidates, increasing manufacturing capacity and implementing better immunization strategy. Here, we report data from a proof-of-concept investigation in two healthy individuals who received two doses of inactivated whole-virus COVID-19 vaccines, followed by a single heterologous boost vaccination after 7 months with an mRNA vaccine candidate (LPP-Spike-mRNA) developed by Stemirna Therapeutics. Following the boost, Spike-specific antibody (Ab), memory B cell and T cell responses were significantly increased. These findings indicate that a heterologous immunization strategy combining inactivated and mRNA vaccines can generate robust vaccine responses and therefore provide a rational and effective vaccination regimen.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
chinese clinical trial registry:ChiCTR2100046504
Funding Statement
The study was supported by the National Key Research and Development Program of China (2020YFC0860300, to H.L), Shanghai Pujiang Talent Program (2020PJD068, to A.L), Shanghai Scientific Development Project (20431900300, to H.L) and internal funds from Stemirna Therapeutics, Inc.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the local ethical committee at Tongji University East Hospital, Shanghai, China. File number. EC.D(BG).016.03.1
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Lead contact: Hangwen Li, lihangwen{at}stemirna.com
Conflict of interest: H.L. is the founder and CEO of Stemirna Therapeutics. A.L., X.M., F.Z., B.Y., M.S., L.H., Y.Z., W.Y., A.Z. are employees of Stemirna Therapeutics. Stemirna Therapeutics filed application on patents entitled “A prophylactic or therapeutical COVID-19 mRNA vaccine” and “An immunization strategy for COVID-19 vaccines”. All other authors declare no conflict of interest.
Data Availability
The data that support the findings of this study are available on request from the corresponding author.
